Association between tipranavir plasma levels and virological response in HIV-infected patients.
The impact of tipranavir plasma levels (TPV C(min)) on virological response was examined in 36 antiretroviral-experienced HIV-infected individuals. Although TPV C(min) did not predict outcome in patients with less than five or more than eight baseline TPV-associated resistance mutations, TPV C(min) values were greater in responders than in nonresponders with five to seven baseline TPV-associated resistance mutations (38.8 vs. 13.8 g/ml, p = 0.017). Thus, therapeutic drug monitoring might be helpful in ensuring a viral response in this subset of patients.
Morello
Judit
J
Hospital Carlos III, Madrid 28029, Spain.
Gascó
Pilar Garcia
PG
Rodriguez-Novoa
Sonia
S
de Mendoza
Carmen
C
Blanco
Francisco
F
Gonzalez-Pardo
Gema
G
Sanz
Beatriz
B
Jimenez-Nacher
Inmaculada
I
Soriano
Vincent
V
D000328:Adult; D019380:Anti-HIV Agents / Q000493:pharmacokinetics*; D024882:Drug Resistance, Viral / Q000235:genetics; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010949:Plasma / Q000737:chemistry / Q000821:virology; D011725:Pyridines / Q000493:pharmacokinetics*; D011753:Pyrones / Q000493:pharmacokinetics*; D013449:Sulfonamides; D016896:Treatment Outcome; D019562:Viral Load
D019380:Anti-HIV Agents; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; C107201:tipranavir